The Post-Marketing Life of Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Human Vaccines and Public Health".
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 2197
Special Issue Editors
Interests: long time immunogenicity of vaccination; adverse events following immunization; vaccination of high risk subgroups
Special Issues, Collections and Topics in MDPI journals
Interests: adverse events following immunization; vaccinology; infectious disease control and prevention
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The recent experience of the SARS-COV-2 pandemic and the universal mass vaccination carried out to fight against this emergency is an important lesson for vaccinologists.
Vaccines against SARS-COV-2 were prepared in 8 months, and a large amount of the information for the safety, long-term immunogenicity, and effectiveness of these vaccines was from post-marketing studies.
This indicates that research on vaccines should not and cannot stop after marketing authorization, as an important portion of evidence actually comes from post-marketing and phase IV studies.
We welcome contributions including original research articles as well as field reviews relating to this research topic.
Prof. Dr. Silvio Tafuri
Dr. Pasquale Stefanizzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- effectiveness of vaccination programs
- safety of vaccines
- long-term immunogenicity
- phase IV studies
